Teva Anticipates “Major Consolidation” In Generic Industry In 2005
Executive Summary
Teva is preparing for another round of consolidation within the generic industry during 2005, North America CEO George Barrett said Jan. 13 at the J.P. Morgan health care conference in San Francisco
You may also be interested in...
Teva/Ivax Merger Will Create Significant Pricing Flexibility In Generics
Teva is prepared to leverage its $7.4 bil. acquisition of Ivax to offer the lowest prices on generic drugs "if need be," Ivax Chairman Phillip Frost said July 26 during a call regarding the deal
Teva/Ivax Merger Will Create Significant Pricing Flexibility In Generics
Teva is prepared to leverage its $7.4 bil. acquisition of Ivax to offer the lowest prices on generic drugs "if need be," Ivax Chairman Phillip Frost said July 26 during a call regarding the deal
Novartis Seeks To Be Generics “Powerhouse” With Eon, Hexal Acquisitions
Novartis expects the addition of Eon Labs and Hexal AG to its Sandoz division to create a generic drug "powerhouse" that will play a major role in the emerging "authorized" generics and follow-on biologics markets